MindMed Reports Second Quarter 2022 Financial Results and Business Highlights
– Phase 2b dose-optimization trial in patients with General Anxiety Disorder underway with first patient dosing expected in Q3 2022 – – Advanced IND-enabling...
Source: prnewswire.com